The vaccine for the coronavirus disease 2019 (Covid-19) offered by Chinese state-owned firm Sinopharm is “very problematic,” Vaccine czar Secretary Carlito Galvez Jr. said on Thursday night.
Galvez said that the price of Sinopharm is “too expensive” at $76 per dose, or about P3,648.
“Even we can cut the price [in] half, it will be seven times higher that AstraZeneca,” Galvez said.
“It doesn’t make sense to buy Sinopharm when you can buy [an] equally safe and effective brand from China and from [the] US with [the] same or higher effects and efficacy,” he added.
Also, when it comes to “sense of fairness, equitable access, and cost efficiency,” Sinopharm will be “very problematic.”
Galvez made the statement ahead of the resumption today (Friday) of a continuing Senate inquiry on the government’s Covid-19 vaccination program. Sinopharm officials will also face the Senate today.
MKG Corporation, the local distributor of Sinopharm, is under fire for claiming that the Department of Health (DOH) failed to act on its application to conduct clinical trials in the Philippines.
The DOH denied such allegations, saying the Philippines’ participation in clinical trials, including Sinopharm’s, was approved as early as may by the Inter-Agency Task Force on Emerging Infectious Diseases.
It was Sinopharm that supplied the Covid-19 vaccines administered on members of the Presidential Security Group. SOVEREIGNPH